These include the receptor ligand pairs MET-HGF, VEGFR2-VEGF-A, FLT3-FLT3L and AXL-GAS6, the hypoxia-related markers CA-9 and clusterin and the micro-environmental factors TIMP2 and TIE2, suggesting that these molecular players and pathways play a role in the tumor, the micro-environment and the systemic response to cabozantinib. The gene discussed is AXL; the disease is neoplasm.